Bacillus subtilis MTCC 5856 and Reduced Disease Severity

• Bacillus coagulans MTCC 5856 supplementation in the management of diarrhea predominant Irritable Bowel Syndrome: a double blind randomized placebo controlled pilot clinical study

  • 2015-12
  • RCT · n = 36
  • Nutrition Journal 15(1)
  • • M. Majeed
    • K. Nagabhushanam
    • Sankaran Natarajan
    • A. Sivakumar
    • Furqan Ali
    • A. Pande
    • Shaheen Majeed
    • S. K. Karri

  • PubMed: 26922379
  • DOI: 10.1186/s12937-016-0140-6

  7 Insights on

  • Reduced Disease Severity

  • High evidence
  • Highly Cited

  Similarly, disease severity also decreased in the patient group receiving B. coagulans MTCC 5856 when compared to placebo group.

  Effect

  Beneficial

  Effect size

  Large